Spanish study tracks real-world use of CLL drug acalabrutinib

NCT ID NCT05999877

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 32 times

Summary

This study follows 192 adults with chronic lymphocytic leukemia (CLL) in Spain who started acalabrutinib as their first treatment or switched to it due to side effects from an older drug. Researchers will track how many patients stay on the drug after 24 months and look at factors like genetic risks and heart conditions. The goal is to see how well acalabrutinib works in real-world settings, not in a controlled trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Almería, Andalusia, 4009, Spain
Research Site

Córdoba, Andalusia, 14004, Spain
Research Site

Granada, Andalusia, 18014, Spain
Research Site

Jaén, Andalusia, 23007, Spain
Research Site

Marbella, Andalusia, 29603, Spain
Research Site

Málaga, Andalusia, 29010, Spain
Research Site

Seville, Andalusia, 41013, Spain
Research Site

Zaragoza, Aragon, 50009, Spain
Research Site

Palma de Mallorca, Balearic Islands, 7010, Spain
Research Site

Palma de Mallorca, Balearic Islands, 7198, Spain
Research Site

Las Palmas de Gran Canaria, Canary Islands, 35016, Spain
Research Site

Las Palmas de Gran Canaria, Canary Islands, 35019, Spain
Research Site

San Cristóbal de La Laguna, Canary Islands, 38320, Spain
Research Site

Santander, Cantabria, 39008, Spain
Research Site

Salamanca, Castille and León, 37007, Spain
Research Site

Segovia, Castille and León, 40002, Spain
Research Site

Valladolid, Castille and León, 47003, Spain
Research Site

Valladolid, Castille and León, 47012, Spain
Research Site

Guadalajara, Castille-La Mancha, 19002, Spain
Research Site

Toledo, Castille-La Mancha, 45004, Spain
Research Site

Barcelona, Catalonia, 8003, Spain
Research Site

Barcelona, Catalonia, 8025, Spain
Research Site

Barcelona, Catalonia, 8035, Spain
Research Site

Barcelona, Catalonia, 8036, Spain
Research Site

Granollers, Catalonia, 8402, Spain
Research Site

L'Hospitalet de Llobregat, Catalonia, 8908, Spain
Research Site

Lleida, Catalonia, 25198, Spain
Research Site

Terrassa, Catalonia, 8221, Spain
Research Site

Ourense, Galicia, 32005, Spain
Research Site

Santiago de Compostela, Galicia, 15706, Spain
Research Site

Vigo, Galicia, 36312, Spain
Research Site

Madrid, Madrid, 28006, Spain
Research Site

Madrid, Madrid, 28031, Spain
Research Site

Madrid, Madrid, 28034, Spain
Research Site

Madrid, Madrid, 28040, Spain
Research Site

Madrid, Madrid, 28041, Spain
Research Site

Madrid, Madrid, 28046, Spain
Research Site

Madrid, Madrid, 28905, Spain
Research Site

Madrid, Madrid, 28911, Spain
Research Site

Majadahonda, Madrid, 28222, Spain
Research Site

El Palmar, Murcia, 30120, Spain
Research Site

Murcia, Murcia, 30008, Spain
Research Site

Oviedo, Principality of Asturias, 33011, Spain
Research Site

Alicante, Valencia, 3010, Spain
Research Site

Valencia, Valencia, 46010, Spain
Research Site

Valencia, Valencia, 46014, Spain
Research Site

Valencia, Valencia, 46026, Spain

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA